Sign in
Back
Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors
Journal article   Open access  Peer reviewed

Outcome of patients with IDH1/2-mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Helen T. Chifotides, Lucia Masarova, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo, …
Blood advances, Vol.4(21), pp.5336-5342
10/11/2020
DOI: https://doi.org/10.1182/bloodadvances.2020001528
PMID: 33112940

Abstract

Key Points IDH1/2-inhibitor–based combinations conferred significant clinical responses in patients with IDH1/2-mutated post–MPN AML. Complete remission was achieved in 3/7 patients (1 attaining MRD–) with new IDH1/2-mutated post–MPN AML treated with IDH1/2-i combinations.
url
https://doi.org/10.1182/bloodadvances.2020001528View
Published (Version of record) Open

Metrics

1 Record Views

Details